grant

Comparative Effectiveness and Safety of Metabolic/Bariatric Surgery, GLP-1, and SGLT-2 Medications for Patients with Obesity and Type 2 Diabetes

Organization KAISER FOUNDATION RESEARCH INSTITUTELocation Oakland, UNITED STATESPosted 6 Mar 2024Deadline 29 Feb 2028
NIHUS FederalResearch GrantFY2026Acute Kidney FailureAcute Kidney InsufficiencyAcute Renal FailureAcute Renal InsufficiencyAdult-Onset Diabetes MellitusAffectAgeAmericanAsianBenefits and RisksBlackBlack raceBlood PressureBlood VesselsBody Weight decreasedCessation of lifeClinicalClinical Practice GuidelineClinical TrialsComparative Effectiveness ResearchComplications of Diabetes MellitusD-GlucoseDataData BasesDatabasesDeathDextroseDiabetes ComplicationsDiabetes MellitusDiabetes-Related ComplicationsDiabetic AcidosisDiabetic ComplicationsDiabetic KetoacidosisDiabetic KetosisDisease ProgressionDrug TherapyDrugsED careER careEffectivenessElectronic Health RecordEligibilityEligibility DeterminationEmergency CareEmergency Department careEmergency Room careEmergency health careEmergency medical careEnrollmentEthnic OriginEthnicityEventFee-for-Service PlansFees for ServiceGLP-1GLP-1 RAGLP-1 agonistGLP-1 analogGLP-1 receptor agonistGU InfectionGastrectomyGastric BypassGenderGenitourinary System InfectionGenitourinary infectionGlp-1Glucagon like peptide 1 agonistGlucagon like peptide-1 receptor agonistsGlucagon-like peptide-1 analogGlucoseGlycohemoglobin AGlycosylated hemoglobin AHb A1Hb A1a+bHb A1cHbA1HbA1cHeadHealth Insurance for Aged and Disabled, Title 18Health Insurance for Disabled Title 18Hemoglobin A(1)HispanicHospital AdmissionHospitalizationHyperglycemiaHypoglycemiaIncidenceInsurance CoverageInsurance StatusKetosis-Resistant Diabetes MellitusKidneyKidney DiseasesKidney Urinary SystemKnowledgeLife StyleLifestyleLinkLongitudinal StudiesLongitudinal SurveysMaturity-Onset Diabetes MellitusMedicalMedicareMedicationMetabolicMicrovascular DysfunctionNIDDMNephropathyNon-Insulin Dependent DiabetesNon-Insulin-Dependent Diabetes MellitusNoninsulin Dependent DiabetesNoninsulin Dependent Diabetes MellitusObesityOperative ProceduresOperative Surgical ProceduresOutcomePatientsPharmaceutical AgentPharmaceutical PreparationsPharmaceuticalsPharmacologic SubstancePharmacological SubstancePharmacological TreatmentPharmacotherapyProtocol ScreeningRaceRacesRandomization trialRandomized, Controlled TrialsRecommendationRenal DiseaseReoperationRepeat SurgeryResearchResearch DesignRiskSGLT 2 inhibitorSGLT2iSafetySample SizeSamplingSelection for TreatmentsSeveritiesSlow-Onset Diabetes MellitusSodium glucose co-transporter 2 inhibitorStable Diabetes MellitusStudy TypeSubgroupSurgicalSurgical InterventionsSurgical ProcedureT2 DMT2DT2DMTherapeuticTitle 18Treatment CostType 2 Diabetes MellitusType 2 diabetesType II Diabetes MellitusType II diabetesWeightWeight LossWeight ReductionWeight maintenance regimenWorkacute kidney injuryadiposityadult adiposityadult obesityadult onset diabetesadults with obesityagesalternative treatmentbariatric surgeryblood glucose regulationbody weight lossclinical practice and guidelinesco-morbidco-morbiditycohortcomorbiditycomparative effectivenesscomparative effectiveness studycomparative safetycompare effectivenesscorpulencecostdata basedata collected in real worlddiabetesdiabetes mellitus therapydiabetes therapydiabetic ketoacidoticdrug interventiondrug treatmentdrug/agentelectronic health care recordelectronic health medical recordelectronic health plan recordelectronic health registryelectronic medical health recordenrollethnic minorityethnic minority groupethnic minority individualethnic minority peopleethnic minority populationgastric bandinggastric bypass surgeryglucagon-like peptide 1glucose controlglucose homeostasisglucose regulationglycemic controlhazardhealth insurance for disabledhemoglobin A1chigh risk grouphigh risk individualhigh risk peoplehigh risk populationhospitalization rateshyperglycemichypoglycemichypoglycemic episodesimplantable gastric stimulation bandingimprovedinfectious disease of genitourinary systemketosis resistant diabeteskidney disorderlong-term studylongitudinal outcome studieslongitudinal research studymacrovascular complicationmacrovascular diseasematurity onset diabetesmicrovascular complicationsmicrovascular diseasemortalityobese patientsobesity interventionobesity managementobesity surgeryobesity therapyobesity treatmentpatient populationpatient subclasspatient subclusterpatient subgroupspatient subpopulationspatient subsetspatient subtypespatients with obesitypharmaceuticalpharmaceutical interventionpharmacological interventionpharmacological therapypharmacology interventionpharmacology treatmentpharmacotherapeuticspreventpreventingprospectiveracialracial backgroundracial minorityracial minority groupracial minority individualracial minority peopleracial minority populationracial originrandomized control trialrandomized trialreal world datarenalrenal disorderresearch studyrural dwellersrural residentsafety outcomessafety studyselection of treatmentsmall vessel diseasestomach bypassstomach staplingstudy designsurgerysurgery risksurgical risktherapy selectiontreatment selectiontype 2 DMtype II DMtype two diabetesuptakeurogenital infectionvascularweight controlweight loss surgeryweight managementweightswt-loss
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Description preview

PROJECT SUMMARY
More than 12 million Americans currently live with both obesity and type 2 diabetes (T2D), putting them in one

of the highest risk groups for developing serious microvascular and macrovascular complications. The Ameri-

can Diabetes Association’s clinical practice guidelines recommend metabolic/bariatric surgery (MBS) and/or…

🔒

Full details available on the Agency plan

Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.

Start 7-day free trial — $29.99/mo →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →
Comparative Effectiveness and Safety of Metabolic/Bariatric Surgery, GLP-1, and SGLT-2 Medications for Patients with Obe | Dev Procure